Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and ...

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 First patient enrolled in ...

modulators Discovery efforts are ongoing for small molecule GIPR modulators for obesity, which have the potential for combination with GLP-1 receptor agonists, such as TERN-601 Terns is prioritizing ...

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 First patient enrolled in ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Seasoned public company CFO with 25 years of leadership experience in biotechFOSTER CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN ...

Veru: Veru's (NASDAQ:VERU) lead asset, enobosarm, an androgen receptor modulator, is currently ... is an ultra-long-acting GLP-1 receptor agonist in Phase 1/2 testing for obesity.

Their pipeline includes clinical stage development programs such as an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 ...

Detailed price information for Terns Pharmaceuticals Inc (TERN-Q) from The Globe and Mail including charting and trades.